Funding Support and Author Disclosures Dr Borlaug has received research support from the National Institutes of Health (NIH) (R01 HL128526 and U01 HL160226) and the United States Department of Defense (W81XWH2210245), as well as research grant funding from AstraZeneca, Axon, GlaxoSmithKline, Medtronic, Mesoblast, Novo Nordisk, and Tenax Therapeutics; has served as a consultant for Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations; and is named inventor (US Patent Number 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Dr Larson has reported that she has no relationships relevant to the contents of this paper to disclose.